75 filings
Page 4 of 4
8-K
q1o8holiqqq
9 May 22
Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:08pm
8-K
bvykmu5cmv2iy1
22 Apr 22
Vallon Pharmaceuticals Announces Review of Strategic Alternatives
9:17am
8-K
8spia48 96nqa8uoke
30 Mar 22
Departure of Directors or Certain Officers
9:26am
8-K
emkgec
21 Mar 22
Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD
7:01am
8-K
itv0l3f7 8118hwe
28 Feb 22
Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors
4:08pm
8-K
ur1e im9v1caheglstw
14 Feb 22
Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update
4:23pm
8-K
cy22d0ky4zysbm4f
23 Dec 21
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
8:36am
8-K
wmlag3fvrkf
12 Nov 21
Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
8:06am
8-K
jn3q5v
12 Oct 21
Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements
9:02am
8-K
a1gduuk3q5 u2dz75ypa
10 Aug 21
Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
8:06am
8-K
2utu7
13 May 21
Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
8:45am
8-K
816hd9imezlkjy
23 Apr 21
Departure of Directors or Certain Officers
4:40pm
8-K
g6wtbp2k9gaolof3g508
14 Apr 21
Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
12:00am
8-K
n2er5ace71 lzryn
26 Feb 21
Regulation FD Disclosure
4:37pm
8-K
2lkm1b9ocfnw
16 Feb 21
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
6:02am